Haptoglobin Diagnostic Test Kit Successful in Determining Cardiovascular Risk in Diabetes Patients
Synvista Therapeutics Inc announces findings from a study that indicated Synvistas proprietary monoclonal enzyme immunoassay can determine a persons haptoglobin pheno/genotype in less than two hours, and can aid physicians in predicting cardiovascular risk in patients with diabetes.
Read More